Corient Private Wealth
LRMR icon

Corient Private Wealth’s Larimar Therapeutics LRMR Stock Holding History

Corient Private Wealth’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.2K Buy
+22,675
New +$90K ﹤0.01% 2972

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Corient Private Wealth's LRMR Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 22,675 shares worth $69.2K. The stake represents ﹤0.01% of the portfolio and ranks #2972 among its holdings.

163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Corient Private Wealth held 22,675 shares of Larimar Therapeutics worth $69.2K as of Q2 2026.
  • Larimar Therapeutics was a new Corient Private Wealth position in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2972 holding.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.